Grand Pharmaceutical Group Limited (Grand Pharma) has filed its monthly return for the period ended 30 June 2026, confirming stable share capital metrics and full compliance with Hong Kong Stock Exchange public-float requirements.

Grand Pharma’s authorised share capital remained unchanged at 100 billion ordinary shares with a par value of HKD 0.01 each, equivalent to HKD 1.00 billion in total.

Issued share capital was steady at 3.55 billion ordinary shares, with no treasury shares outstanding and no issuance, cancellation or repurchase activity during the month.

The company affirmed that its public float continues to meet the Main Board’s minimum 25% threshold, ensuring ongoing adherence to Listing Rule 13.32D(1).

Grand Pharma reported no movements in share options, warrants, convertible securities, or other equity arrangements, and confirmed that no Hong Kong Depositary Receipts were outstanding.

The filing, dated 2 July 2026, was signed by Company Secretary Victor Foo Tin Chung, who certified compliance with all relevant regulatory and listing requirements.